RESUMO
Three pyridazinyl-gamma-aminobutyric acid (GABA) derivatives, SR 95103, SR 42641 and SR 95531, have previously been shown to be specific, competitive and reversible GABAA antagonists. For all three compounds selectivity was claimed mainly on the basis of biochemical results. However the absence of an interaction with the binding site for strychnine does not preclude an interaction with the glycine receptor. Therefore the interaction between these compounds and GABA- and glycine-elicited responses in the rat cuneate nucleus was examined in vivo by microiontophoretic techniques using extracellular recordings. Preliminary experiments in the somesthetic cortex of the rat (18 cells) confirmed that SR 95103 (100 mM; 0-100 nA) blocked GABA-evoked responses. In the cuneate nucleus SR 95103 (100 mM), SR 42641 (5 mM), SR 95531 (5 mM) and bicuculline methochloride (BMC; 5 mM) blocked GABA-elicited responses in a dose-dependent, competitive and reversible fashion for ejection currents up to 100 nA. The compound SR 95103 appeared to be less potent than bicuculline and also antagonized glycine-induced responses. Both SR 42641 and SR 95531 appeared to be equipotent to bicuculline and selective for the GABA receptor. Based on these results, it is postulated that SR 42641 and SR 95531 are potent and reversible GABAA antagonists and could be useful tools to further characterize the GABA receptor.
Assuntos
Bulbo/efeitos dos fármacos , Piridazinas/farmacologia , Receptores de GABA-A/efeitos dos fármacos , Receptores de Neurotransmissores/efeitos dos fármacos , Ácido gama-Aminobutírico/análogos & derivados , Vias Aferentes/efeitos dos fármacos , Animais , Iontoforese , Masculino , Microinjeções , Ratos , Ratos Endogâmicos , Receptores de GlicinaRESUMO
SR 95531 has been shown to be a potent, selective, reversible and competitive GABAA antagonist. In the present study we report that (3H)SR 95531 binds with high affinity and in a specific and saturable manner to rat brain membranes. Scatchard analysis revealed two binding sites (KD: 6 nM; Bmax: 0.24 pmol/mg protein and KD: 38 nM; Bmax: 0.66 pmol/mg protein). Only GABA ligands were effective displacers of (3H)SR 95531. The respective IC50 values obtained with these compounds suggests that (3H)SR 95531 labels the GABA receptor in its antagonist conformation.
Assuntos
Encéfalo/metabolismo , Antagonistas GABAérgicos , Piridazinas/metabolismo , Receptores de GABA-A/metabolismo , Animais , Sítios de Ligação , Ligação Competitiva , Cinética , Masculino , Conformação Molecular , Ratos , Ratos Endogâmicos , Membranas Sinápticas/metabolismoRESUMO
A series of 6-aryl-3-(hydroxypolymethyleneamino)pyridazines derivatives was synthesized and evaluated for anticonvulsant activity. The compounds were screened in mice for their ability to antagonize maximal electroshock- and bicuculline-induced seizures; neurotoxicity was evaluated in the rotorod test. The anticonvulsant activity of the most potent compounds in this series was also examined in kindled amygdaloid rats and in photoepileptic Papio papio baboons. Phenobarbital, diphenylhydantoin, carbamazepine, and sodium valproate were used as standard antiepileptic drugs. The structure-activity relationships in this series were examined by either varying the aryl ring in the 6-position of the pyridazine ring or by modifying the 3-amino side chain. Only the compounds with a phenyl ring in the 6-position of the pyridazine ring exhibited appreciable anticonvulsant activity. Furthermore, a 4-hydroxypiperidine side chain in the 3-position of the pyridazine ring appeared essential for anticonvulsant activity. Substituting the phenyl ring with a Cl in the 2-position led to a substantial increase of activity; disubstituting the phenyl ring with a Cl in the 2- and 4-positions yielded the most potent compounds in this series, some of which were as potent or more potent than phenobarbital. Two compounds, 6-(2-chlorophenyl)-3-(4-hydroxypiperidino)pyridazine (2) and 6-(2,4-dichlorophenyl)-3-(4-hydroxypiperidino)pyridazine (3), were selected for further studies. Clinical evaluation of these compounds is in progress.
Assuntos
Anticonvulsivantes/síntese química , Piridazinas/síntese química , Animais , Bicuculina/antagonistas & inibidores , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Eletrochoque , Feminino , Hipnóticos e Sedativos , Excitação Neurológica/efeitos dos fármacos , Masculino , Camundongos , Destreza Motora/efeitos dos fármacos , Papio , Pentilenotetrazol/antagonistas & inibidores , Estimulação Luminosa , Piridazinas/farmacologia , Ratos , Ratos Endogâmicos , Convulsões/induzido quimicamente , Convulsões/tratamento farmacológico , Convulsões/etiologia , Relação Estrutura-AtividadeRESUMO
Minaprine [3-[(beta-morpholinoethyl)amino]-4-methyl-6-phenylpyridazine dihydrochloride] is active in most animal models of depression and exhibits in vivo a dual dopaminomimetic and serotoninomimetic activity profile. In an attempt to dissociate these two effects and to characterize the responsible structural requirements, a series of 47 diversely substituted analogues of minaprine were synthesized and tested for their potential antidepressant, serotonergic, and dopaminergic activities. The structure-activity relationships show that dopaminergic and serotonergic activities can be dissociated. Serotonergic activity appears to be correlated mainly with the substituent in the 4-position of the pyridazine ring whereas the dopaminergic activity appears to be dependent on the presence, or in the formation, of a para-hydroxylated aryl ring in the 6-position of the pyridazine ring.
Assuntos
Antidepressivos/síntese química , Dopaminérgicos/síntese química , Piridazinas/síntese química , Receptores de Serotonina/efeitos dos fármacos , Animais , Fenômenos Químicos , Química , Feminino , Camundongos , Piridazinas/farmacologia , Receptores Dopaminérgicos/efeitos dos fármacos , Relação Estrutura-AtividadeRESUMO
Partial ablation of the left fronto-parietal cerebral cortex decreases the number of spleen T cells, impairs IgG-alpha SRBC and T mitogen-induced responses, and delays the response to alloantigens. In contrast, these events are increased following a symmetric lesion of the right neocortex. The findings extend previous results showing that the neocortex modulates NK activity and the efficacy of T cell-specific serum factors. B cells and macrophages are not affected. In these assays, mice subjected to ablation of one lateral cerebral neocortex serve as controls for symmetrically lesioned mice, in addition to no surgery or sham-operated controls. The findings suggest that brain lateralization for cognitive processes should be extended to T cell immune recognition. The phenomenon is present at a population level.
Assuntos
Córtex Cerebral/imunologia , Imunidade Celular , Linfócitos T/imunologia , Animais , Dominância Cerebral , Contagem de Leucócitos , Camundongos , Camundongos Endogâmicos C3H , Baço/imunologiaRESUMO
To investigate further the structural requirements for benzodiazepine (BZD) receptor ligands, we synthesized SR 95195, [7-phenyl-3-methyl-1,2,4-triazolo-(4,3-b) pyridazine], a positional isomer of the 6-phenyl-triazolo-pyridazines, which were the first non-BZD derivatives to exhibit high affinity for the BZD receptor and BZD-like activity in vivo. In vitro, SR 95195 displaced specifically bound [3H]-flunitrazepam from rat cerebellar and hippocampal membranes with respective IC50 values of 4 and 8 microM. In vivo, SR 95195 lacked BZD-like activity. At high doses SR 95195 induced clonic seizures in mice (threshold convulsant dose: 150 mg kg-1; CD50: 160 mg kg-1 i.p.) which were antagonized by Ro 15-1788. At non-convulsant doses (25 mg kg-1 i.p. and 100 mg kg-1 i.p.) SR 95195 significantly decreased punished responding in an operant conflict procedure in the rat, suggesting SR 95195 has intrinsic anxiogenic activity. SR 95195, in mice, reversed the anticonvulsant and myorelaxant actions of diazepam 3 mg kg-1, orally (respective ED50 values: 45 mg kg-1 i.p. and 44 mg kg-1 i.p.). In an operant-conflict test in rats, SR 95195 at non-anxiogenic doses, antagonized the disinhibitory action of diazepam 4 mg kg-1, i.p. (ED50: 8.6 mg kg-1, i.p.), but not that of pentobarbitone 15 mg kg-1, i.p. It is concluded that SR 95195 has the pharmacological profile of an inverse BZD agonist and that displacing the phenyl from the 6- to the 7-position in the triazolopyridazine series causes a shift from agonist to inverse agonist type activity at the BZD receptor site.
Assuntos
Convulsivantes , Piridazinas/farmacologia , Receptores de GABA-A/metabolismo , Animais , Ligação Competitiva , Encéfalo/metabolismo , Condicionamento Operante/efeitos dos fármacos , Diazepam/antagonistas & inibidores , Feminino , Flumazenil/metabolismo , Flumazenil/farmacologia , Flunitrazepam/metabolismo , Técnicas In Vitro , Masculino , Camundongos , Piridazinas/metabolismo , Ratos , Ratos Endogâmicos , Relação Estrutura-AtividadeRESUMO
The antidepressant minaprine (3-(2-morpholino-ethylamino) 4-methyl 6-phenyl pyridazine, dihydrochloride) and its main metabolites were examined for their monoamine oxidase (MAO) inhibitory effects in the rat. In our experimental conditions, minaprine displayed in vitro a very weak affinity for brain MAO A and B with IC50S close to 1 mM. However, ex vivo, after intraperitoneal administration, this drug behaved as a specific and short-acting type A MAO inhibitor (MAOI) of mild potency (ED50 = 12.8 mg/kg). In comparison, the reversible type A MAOIs, moclobemide and cimoxatone, were respectively 14 and 15 times more potent. When administered orally, minaprine proved to be considerably less active. The results presented in this study suggest that minaprine inhibits MAO A mainly after being converted into active metabolites. However, the chloroform extractable metabolites were found inactive in vitro towards this enzyme, suggesting that MAO inhibitory activity is mediated by one or more other non-identified metabolites.
Assuntos
Antidepressivos/farmacologia , Inibidores da Monoaminoxidase/farmacologia , Piridazinas/farmacologia , Animais , Biotransformação , Corpo Estriado/enzimologia , Técnicas In Vitro , Cinética , Fígado/enzimologia , Masculino , Proadifeno/farmacologia , Piridazinas/metabolismo , Ratos , Ratos EndogâmicosRESUMO
In order to investigate the behavioural effect of selective blockade of M1 muscarinic receptors in the forebrain, and to characterize a new model for the evaluation of muscarinic agonistic activity, the effect of intrastriatally injected pirenzepine was studied in mice. The direct injection of pirenzepine (0.01-1 microgram/mouse) into the right striatum of conscious mice resulted in contralateral turning behaviour. When injected intraperitoneally (IP) 15 min before pirenzepine (1 microgram), the muscarinic receptor agonists arecoline and pilocarpine (0.3-3 mg/kg), oxotremorine (0.003-0.03 mg/kg) and RS 86 (0.03-1 mg/kg) antagonized pirenzepine-induced turning, as did the choline-esterase inhibitor physostigmine (0.01-0.1 mg/kg) and the nootropic drug aniracetam (10-30 mg/kg). Haloperidol (0.03-0.3 mg/kg IP) weakly, but significantly, decreased the effect of pirenzepine, whereas (+/-) sulpiride (3-100 mg/kg) failed to affect it. Finally, (+/-)-amphetamine (0.1-3 mg/kg IP), citalopram (1-30 mg/kg IP) and muscimol (0.03-0.3 mg/kg IP) failed to modify pirenzepine-induced turning when administered prior to intrastriatal pirenzepine. These results suggest an involvement of M1 muscarinic receptors in rotational behaviour, and indicate that pirenzepine-induced turning may represent a new model for studying the central activity of cholinomimetic drugs.
Assuntos
Comportamento Animal/efeitos dos fármacos , Parassimpatomiméticos/farmacologia , Pirenzepina/antagonistas & inibidores , Animais , Antipsicóticos/farmacologia , Citalopram , Corpo Estriado , Dextroanfetamina/farmacologia , Interações Medicamentosas , Feminino , Injeções , Camundongos , Muscimol/farmacologia , Pirenzepina/administração & dosagem , Pirenzepina/farmacologia , Propilaminas/farmacologiaRESUMO
The discriminative stimulus properties of scopolamine, a potent antagonist at muscarinic receptors, were used for testing the discriminative effects of drugs known to act on cholinergic transmission. Rats were trained in a standard two-bar operant conditioning procedure with food as the reinforcer, according to a FR10 schedule. The training dose of scopolamine was progressively reduced from 0.25 mg/kg SC to the low dose of 0.062 mg/kg SC. Scopolamine yielded an accurate discrimination in all the six rats tested. The generalization gradient resulted in an ED50 of 0.027 mg/kg. The scopolamine cue lasted for 1 h and was of central origin, since it was not mimicked by scopolamine methylbromide. The scopolamine stimulus generalized to atropine and trihexyphenidyl (respective ED50 values 2.20 and 0.21 mg/kg SC). Atropine depressed rate of responding, while trihexyphenidyl did not. Antagonism experiments with both direct agonists at the muscarinic receptor (arecoline and oxotremorine) and indirect agonists, i.e., inhibitors of the acetylcholine esterase [physostigmine and tetrahydroaminoacridine (THA)], led to inconsistent results. Increasing the doses of the agonists in order to block the scopolamine cue may be limited by their rate suppressant effect on responding. Based upon previously published results, it is suggested that the muscarinic agonist cue is more useful than the antagonist cue for investigating muscarinic transmission.
Assuntos
Discriminação Psicológica/efeitos dos fármacos , Escopolamina/farmacologia , Animais , Atropina/farmacologia , Condicionamento Operante/efeitos dos fármacos , Sinais (Psicologia) , Relação Dose-Resposta a Droga , Alimentos , Generalização Psicológica/efeitos dos fármacos , Masculino , Parassimpatolíticos/farmacologia , Ratos , Fatores de Tempo , Triexifenidil/farmacologiaRESUMO
In order to validate a new animal model predictive of the profile of antiepileptic drugs, we studied the antagonism by standard antiepileptics of the EEG modifications induced by low-speed IV infusion of pentylenetetrazol (PTZ) in rats. The activity of the drugs was measured by their effects on temporal characteristics of the PTZ-induced EEG paroxysms. Most compounds had moderate to potent anti-PTZ effects, as shown by the changes in the EEG temporal parameters. However, these effects depended on the drugs and doses. Cluster analysis showed that drugs and doses which evoked similar changes were closely related and were included in separate clusters with respect to one another. In particular, the present results showed that benzodiazepines and antiepileptics cluster differently in their effects. Thus, this model could be a useful tool for assessing new antiepileptic drugs.
Assuntos
Anticonvulsivantes , Eletroencefalografia , Pentilenotetrazol/antagonistas & inibidores , Animais , Anticonvulsivantes/farmacologia , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Epilepsia , Epilepsia Tipo Ausência/tratamento farmacológico , Masculino , Ratos , Ratos EndogâmicosRESUMO
The recognition of an unfamiliar juvenile rat by an adult rat has been shown to imply short-term memory processes. In this study the effect of various psychotropic drugs on this investigatory behaviour was examined. The procedure was as follows: an unfamiliar juvenile rat was placed in the home cage of an adult rat for 5 min. The time spent by the adult rat in investigating the juvenile was recorded. The adult rat was then immediately treated with vehicle or test compounds, and was again exposed for 5 min to the same juvenile 2 h later. At this time point vehicle-treated rats no longer recognized the juvenile rat, i.e. the time of investigation was similar to that observed during the first presentation. Arecoline (1 and 3 mg/kg IP), physostigmine (0.05 and 0.1 mg/kg SC), RS86 (0.5 mg/IP) and nicotine (0.125 and 0.5 mg/kg IP) reduced in a dose-dependent fashion the time spent in investigating the juvenile during the second exposure. This result cannot be attributed to nonspecific effects, since it was not observed when a different juvenile was used for the second exposure. The effect of arecoline was reversed by scopolamine, but not by methylscopolamine. Aniracetam reduced investigatory behaviour at the dose of 50 mg/kg IP. FG 7142 (5 mg/kg IP) and beta-CCM (0.4 mg/kg IP) were also active and their effect was reversed by Ro 15-1788. DL-Amphetamine (0.5 and 1 mg/kg IP), nomifensine (1.25-10 mg/kg IP) and strychnine (0.25 and 0.5 mg/kg IP) were ineffective or reduced this behaviour unspecifically.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Ansiolíticos/farmacologia , Estimulantes do Sistema Nervoso Central/farmacologia , Memória/efeitos dos fármacos , Parassimpatomiméticos/farmacologia , Psicotrópicos/farmacologia , Comportamento Social , Animais , Arecolina/farmacologia , Benzodiazepinas , Carbolinas/farmacologia , Relação Dose-Resposta a Droga , Masculino , Pirrolidinonas/farmacologia , Ratos , Ratos EndogâmicosRESUMO
L-[3H]Glutamic acid binds reversibly to rat brain membranes with high affinity. Specific binding is linear with tissue concentration and has a pH optimum at neutrality. Saturation isotherms reveal anomolous kinetics of specific binding with an high affinity site with a KD of 11 nM and a lower affinity site with a KD of 80 nM; the Scatchard plots intercept at a common bound/free ratio. Hill plots of the complete saturation isotherms have a slope of 1.0. There are marked regional differences in the distribution of binding sites in rat brain: parietal cortex, frontal cortex, hippocampus greater than striatum greater than thalamus greater than cerebellum, pons-medulla and hypothalamus. Except for a small amount of specific binding in heart, other peripheral tissues do not exhibit specific binding of L-[3H]glutamic acid. Several amino acids with neuroexcitatory effects inhibit the specific binding: L-glutamic acid greater than L-aspartic acid and D,L-homocysteic acid greater than D-glutamic acid and L-cysteine sulfinic acid; related amino acids without neuroexcitatory effects do not inhibit specific binding. Reputed antagonists of glutamate-induced neuronal depolarization block specific binding: alpha-aminoadipic acid greater than 2-amino,4-phosphonobutyric acid greater than glutamate diethylester. Prior kainate lesion of the neurons intrinsic to the striatum results in a 45% decrement in specific binding of L-[3H]glutamic acid whereas cortical ablation, which causes degeneration of a cortical-striatal glutamatergic projection and reduces striatal glutamate synaptosomal uptake, does not affect specific binding. These results are compatible with the interpretation that the binding of [3H]glutamic acid occurs at excitatory receptors on neurons.
Assuntos
Sítios de Ligação , Encéfalo/metabolismo , Glutamatos/metabolismo , Membranas Sinápticas/metabolismo , Animais , Sítios de Ligação/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Mapeamento Encefálico , Córtex Cerebral/fisiologia , Relação Dose-Resposta a Droga , Antagonistas de Aminoácidos Excitatórios , Glutamatos/administração & dosagem , Masculino , Vias Neurais/fisiologia , Ratos , Membranas Sinápticas/efeitos dos fármacosRESUMO
An arylaminopyridazine derivative of gamma-aminobutyric acid (GABA), SR 95103, has been shown to be a selective antagonist of GABA at the GABAA receptor site. Subsequent structure-activity studies showed that suppressing the methyl in the 4-position of the pyridazine ring, and substituting the phenyl ring at the para position with a chlorine (SR 42641) or a methoxy group (SR 95531) led to compounds which exhibited the highest affinities for the GABA receptor site in this series. In the present study we examined the biochemical interaction of these compounds with the GABA receptor as well as their biochemical selectivity for this receptor. SR 95531 and SR 42641 displaced [3H]GABA from rat brain membranes with apparent Ki values of 0.15 microM and 0.28 microM respectively and Hill numbers near 1.0. The two compounds antagonized the GABA-elicited enhancement of [3H]diazepam-binding in a concentration-dependent manner without affecting [3H]diazepam-binding per se. Scatchard and Lineweaver-Burk analysis of the interaction of the two compounds with the GABAA receptor sites, revealed that the compounds were competitive at the high affinity site, but non-competitive at the low affinity site. Neither compound interacted with other GABAergic processes or with a variety of central receptor sites. When administered intravenously, SR 95531 and SR 42641 elicited tonic-clonic seizures in mice. Based on these results, it is postulated that SR 95531 and SR 42641 are specific, potent and competitive GABAA antagonists.
Assuntos
Encéfalo/metabolismo , Piridazinas/metabolismo , Receptores de GABA-A/metabolismo , Animais , Ligação Competitiva , Diazepam/metabolismo , Cinética , Masculino , Ratos , Ratos Endogâmicos , Relação Estrutura-Atividade , Membranas Sinápticas/metabolismo , Ácido gama-Aminobutírico/metabolismoRESUMO
Two pyridazinyl GABA derivatives, SR 95103 and SR 42641 have recently been described as selective GABAA receptor antagonists. We have now investigated the behavioural effects of SR 95103 and SR 42641 after intrastriatal injection in mice. When injected into the right striatum, SR 95103 (0.01-0.5 microgram), SR 42641 (0.0001-0.01 microgram) and bicuculline methiodide (0.005-0.05 microgram) induced contralateral rotations which were antagonized by intraperitoneal injection of muscimol. In contrast, the intrastriatal injection of the GABAA receptor agonist muscimol induced ipsilateral rotations. Muscimol-induced turning was antagonized by SR 95103 (10-30 mg/kg), SR 42641 (1-10 mg/kg) and (+)-bicuculline (0.125-0.5 mg/kg) injected intraperitoneally, but not by strychnine. Intrastriatal glycine also induced ipsilateral rotations which were antagonized by strychnine (0.01-0.3 mg/kg i.p.) but not by (+)-bicuculline, SR 95103 or SR 42641. These results suggest that SR 95103 and SR 42641 induce turning through a selective blockade of GABAA receptors within the striatum.
Assuntos
Comportamento Animal/efeitos dos fármacos , Corpo Estriado/efeitos dos fármacos , Piridazinas/farmacologia , Receptores de GABA-A/efeitos dos fármacos , Análise de Variância , Animais , Bicuculina/análogos & derivados , Bicuculina/farmacologia , Dopamina/fisiologia , Relação Dose-Resposta a Droga , Feminino , Glicina/farmacologia , Camundongos , Muscimol/farmacologia , Estricnina/farmacologiaRESUMO
In rats, mixed M1/M2 muscarinic ligands induce a discrimination which is of central origin and selectively mediated by either one or both muscarinic receptor subtypes. In the present study we examined the effects of intracerebroventricular (i.c.v.) pirenzepine, a relatively selective M1 receptor antagonist which does not cross the blood-brain barrier, on muscarinic discriminations. Groups of six rats were trained to discriminate, in a two-lever operant task, either 0.062 mg/kg subcutaneous (s.c.) scopolamine or 0.075 mg/kg s.c. oxotremorine. When the rats had been well trained in the procedure, the discriminative effects of various i.c.v. muscarinic ligands were examined. Scopolamine (1.5-12 micrograms i.c.v.), but not pirenzepine (20-40 micrograms i.c.v.), generalized to s.c. scopolamine. Oxotremorine (0.75-6 micrograms i.c.v.) generalized to s.c. oxotremorine. Scopolamine (12 micrograms i.c.v.), but not pirenzepine (20-40 micrograms i.c.v.), antagonized the oxotremorine cue. These results suggest that activation of the M1 receptor is not the prominent component of muscarinic stimulus control.
Assuntos
Discriminação Psicológica/efeitos dos fármacos , Pirenzepina/farmacologia , Receptores Muscarínicos/efeitos dos fármacos , Animais , Injeções Intraventriculares , Masculino , Oxotremorina/farmacologia , Pirenzepina/administração & dosagem , Ratos , Escopolamina/farmacologiaRESUMO
The behavioural effect of intrastriatally injected cholecystokinin sulphated octapeptide (CCK-8S), and its interactions with the antagonists Z-CCK-(27-32)NH2 and proglumide, were investigated in mice. When injected into the right striatum, CCK-8S (0.05-1 ng) induced contralateral rotations, as did the dopamine agonist apomorphine. Non-sulphated CCK-8 was inactive and sulphated desamino-CCK-7 was only weakly active in this respect. CCK-8S-induced turning was antagonized by co-injected Z-CCK-(27-32)NH2 (0.01-10 ng) or proglumide (0.1-1 micrograms), as well as by intraperitoneal injection of the neuroleptic drug haloperidol. These data suggest that CCK-8S may, in these conditions, stimulate dopamine-mediated neurotransmission, and that Z-CCK-(27-32)NH2, in addition to its peripheral effect, is also a very potent CCK antagonist at the striatal level.
Assuntos
Receptores Dopaminérgicos/efeitos dos fármacos , Sincalida/farmacologia , Animais , Apomorfina/farmacologia , Corpo Estriado , Interações Medicamentosas , Feminino , Haloperidol/farmacologia , Injeções , Camundongos , Proglumida/farmacologia , Sincalida/administração & dosagem , Comportamento Estereotipado/efeitos dos fármacosRESUMO
SR 95103 has recently been described as a selective GABAA antagonist. In this study, the electroencephalographic (EEG) effects of SR 95103 were investigated as well as its central interaction with inhibitory amino acids and muscimol. Slow intravenous infusions of SR 95103 in rats induced epileptiform EEG activities which were antagonized by intracerebroventricularly injected muscimol, GABA and taurine whereas glycine did not modify and even facilitated the effects of SR 95103. These results suggest that the EEG effects of SR 95103 are due to the specific GABAA antagonistic properties of this compound.
Assuntos
Eletroencefalografia , Glicina/farmacologia , Muscimol/farmacologia , Piridazinas/farmacologia , Receptores de GABA-A/efeitos dos fármacos , Taurina/farmacologia , Animais , Interações Medicamentosas , Masculino , Ratos , Ratos Endogâmicos , Convulsões/induzido quimicamente , Ácido gama-Aminobutírico/farmacologiaRESUMO
Pyridazinyl derivatives of gamma-aminobutyric acid (GABA) have recently been shown to be selective, reversible and competitive GABAA antagonists. Unlike what is observed with all other GABAA antagonists, the affinity of these compounds for the GABAA receptor is not modified by thiocyanate. The chemical structure of these pyridazinyl-GABA derivatives differs from that of other GABAA antagonists by the presence of a free carboxylic group in their structure. We speculated that this could explain their lack of sensitivity to thiocyanate. Consequently, we synthesized three structural analogues of these pyridazinyl-GABA derivatives in which we replaced the free carboxyl group by a cyano group. These compounds displaced [3H]GABA from rat brain membranes and reversed the GABA-induced enhancement of [3H]diazepam binding. However their affinity for the GABAA receptor increased 10- to 20-fold in the presence of thiocyanate. Thus, sensitivity to thiocyanate appears to be related more to the absence of an anionic functional group than to the agonist or antagonist nature of the GABAA ligand.
Assuntos
Antagonistas GABAérgicos , Piridazinas/metabolismo , Tiocianatos/farmacologia , Animais , Ligação Competitiva , Encéfalo/metabolismo , Diazepam/metabolismo , Técnicas In Vitro , Ratos , Receptores de GABA-A/metabolismo , Relação Estrutura-Atividade , Ácido gama-Aminobutírico/análogos & derivados , Ácido gama-Aminobutírico/metabolismoRESUMO
In order to design a selective M1 muscarinic agonist, we synthesized SR 95639A (morpholinoethylamino-3-benzocyclohepta-(5,6-c)-pyridazine, dihydrochloride), a semi-rigid analogue of the aminopyridazine antidepressant drug minaprine. SR 95639A displaced [3H]pirenzepine from its binding sites in rat hippocampal membranes with an IC50 value of 0.27 microM. It only weakly displaced [3H]N-methylscopolamine from cerebellar, cardiac and ileal membranes (10-48 microM), and, up to 100 microM, did not interact with the main other receptors of the rat brain. In rat isolated sympathetic ganglia, SR 95639A induced dose-dependent depolarizations which were antagonized by pirenzepine, and dose dependently suppressed the M current. These latter effects were also pirenzepine-sensitive. After i.p. or oral treatment in mice, SR 95639A never induced the classical cholinergic syndrome, up to lethal doses. Finally, SR 95639A (i.p. and p.o.) antagonized contralateral rotations induced by intrastriatal injection of pirenzepine, in mice. These results suggest that SR 95639A is a selective agonist at central muscarinic M1 receptors and may represent a useful tool for further characterization of the nature and function of muscarinic receptor subtypes.
Assuntos
Morfolinas/farmacologia , Parassimpatomiméticos/farmacologia , Piridazinas/farmacologia , Animais , Comportamento Animal/efeitos dos fármacos , Cisterna Magna , Relação Dose-Resposta a Droga , Eletrofisiologia , Cobaias , Técnicas In Vitro , Injeções , Masculino , Relaxamento Muscular/efeitos dos fármacos , N-Metilescopolamina , Pirenzepina/antagonistas & inibidores , Pirenzepina/farmacologia , Ratos , Ratos Endogâmicos , Receptores Muscarínicos/efeitos dos fármacos , Receptores Muscarínicos/metabolismo , Derivados da Escopolamina/farmacologia , Comportamento Estereotipado/efeitos dos fármacosRESUMO
Alterations in gamma-aminobutyric acid (GABA) metabolism have been investigated in the kindling model of epilepsy. Numerous generalized seizures were induced by amygdala-kindling stimulations in rats. One week after the last stimulation, there were no changes in GABA levels nor in the activity of enzymes responsible for the synthesis (glutamic acid decarboxylase) and catabolism (GABA transaminase and succinyl semialdehyde dehydrogenase). These results do not exclude other changes in GABA function as modifications of transport or receptors.